- Molecular NameSpirapril
- SynonymNA
- Weight466.623
- Drugbank_IDDB01348
- ACS_NO52-01-7
- Show 3D model
- LogP (experiment)3.89
- LogP (predicted, AB/LogP v2.0)1.38
- pkaN/A
- LogD (pH=7, predicted)-2.15
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.28
- LogSw (predicted, AB/LogsW2.0)66.1
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors2
- No.of HBond Acceptors7
- No.of Rotatable Bonds10
- TPSA146.54
- StatusFDA approved
- AdministrationN/A
- PharmacologyN/A
- Absorption_valueN/A
- Absorption (description)Bioavailability is 50% following oral administration.
- Caco_2N/A
- Bioavailability50.0
- Protein bindingN/A
- Volume of distribution (VD)57.5 L (healthy individuals); 48.5 L (patients with liver cirrhosis); 83.3 L (non-cirrhotic liver disease).
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Converted to spiraprilat following oral administration.
- Half lifeSpirapril (oral administration in healthy volunteers) 0.9 to 1.6 h; spiraprilat (biphasic disposition) approximately 1 to 2 h and 30 to 40 h.
- ExcretionHepatic and renal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityHypotension, arrhytmias, leukopenia, thrombocytopenia, anemia. Dry mouth, dyspepsia, taste perversion. Fatigue, dizziness, headache, sleepiness Pruritis, angioneurotic edema, cutaneous eruption.
- LD50 (rat)N/A
- LD50 (mouse)N/A